Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals is preparing to enter the market for semaglutide, the blockbuster weight-loss drug, as Novo Nordisk’s patent protection expires early next year. The company aims to release both oral and injectable forms, with Phase 3 trials for oral semaglutide underway and partnerships secured for injectables. Executives revealed that Torrent is positioned to be among the first to launch generic semaglutide, potentially enhancing its chronic medicine portfolio within the next two years. This bold move comes amid strong financials: Q1 revenue jumped 11% to ₹3,178 crore Net profit soared 20% to ₹548 crore Operating EBITDA rose 14% to ₹1,032 crore, with margins at 32.5%   Torrent’s upcoming launch coincides with its acquisition of JB Pharma, worth ₹11,917 crore for a 46.39% stake, triggering a mandatory open offer for additional shares. JB Chemicals shareholders will receive 51 Torrent shares for every 100 JB Chemicals shares. With rising global demand for weight-loss therapies, Torrent’s aggressive entry into the semaglutide market could reshape its growth trajectory and shake up the diabetes and obesity drug segment in India.

Mumbai: Ahmedabad-based drugmaker Torrent Pharmaceuticals in Q1 FY2025-26 reported a revenue of ₹3,178 crore, up by 11 per cent on year-on-year (YoY) basis against the same quarter of previous fiscal. During the period net profit rose by 20 per cent to ₹548 crore, attributed with strong sales momentum across “key territories.” For the April-June quarter the company Operating Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBIDTA) stood at ₹1,032 crore, at an operating margin of 32.5 per cent. The company India sales–which accounts for nearly 50 per cent of the total revue—grew by 11 per cent to ₹1,811 crore, where the chronic therapy segment outpaced the gross market growth by 4 percentage points. Meanwhile the company’s international businesses also reported positive revenue growth, with US sales notably increasing by 19 per cent to ₹308 crore, where its recent launches are stated to have achieved their targeted market shares. A major announcement from the common in the quarter was the acquisition of JB Chemicals & Pharmaceuticals controlling stakes from KKR for ₹19,500 crore—around ₹12,275 crore for KKR (46 per cent) and company employees 2.8 per cent) and an additional acquisition of 26 per cent equity shares from open market at a face value of ₹1,639, amounting to ₹6,826 crore. By Online Bureau ,

Mumbai: Torrent Pharmaceuticals is planning to catch the first wave of semaglutide launch once Danish drugmaker Novo Nordisk 's patent expires early next year. The Ahmedabad-based company is looking to be present in both oral and injectable versions of the weight loss drug , a top executive said. Torrent is currently conducting Phase 3 clinical trials for oral products while it has also partnered for the injectables. "As of now it looks like we could be in the first wave....it will be a reasonable addition to our chronic medicine portfolio in the next 1-2 years," company officials said over an investor call on Monday. The company reported an 11% growth in its first quarter revenue to ₹3,178 crore, while net profit was ₹548 crores, up 20% y-o-y. Its operating EBITDA stood at ₹1,032 crore, up 14% y-o-y, while EBITDA margin was at 32.5%. The operating EBITDA includes acquisition-related one-off expenses of ₹15 crore. On JB Pharma acquisition , Aman Mehta, whole time director, Torrent Pharma, said that the acquisition was on track. "There were some filings required in terms of public offer and merger schemes including the CCI application, all those have been done now. We have to now wait for the CCI to revert and see if there are incremental things to be done," he said. The company will acquire 46.39% equity stake (on a fully diluted basis) of JB Pharma through a share purchase agreement for ₹11,917 crore at ₹1,600 per share. This will trigger a mandatory open offer to acquire up to 26% of JB Pharma shares from public shareholders at an open offer price of ₹1,639.18 per share. Torrent has also expressed its intent to acquire up to 2.80% of equity shares from employees of JB Chemicals at transaction price. JB Chemicals shareholders will get 51 equity shares of Torrent for every 100 equity shares of JB Chemicals.